Webinar

This program will introduce CCM® therapy as a therapy option for treating NYHA Stage III Heart Failure patients that remain symptomatic despite being on optimal medical treatment. The faculty will explain and break down the mechanism of action of cardiac contractility modulation. The faculty will discuss the screening process for eligible CCM patients from the EP and HF clinical workflow perspectives. Utilizing their personal experience, our thought leaders will explore and describe their experience with CCM and illustrate real-life patient responses to the therapy. The session will also offer case studies to demonstrate processes and outcomes. Lastly, we will allow time for questions and answers to encourage participation and foster a valuable discussion.